Diversification of antitumour immunity in a patient with metastatic melanoma treated with ipilimumab and an IDO-silenced dendritic cell vaccine

Case Reports in Medicine

Volumn 2016, Issue , 2016, Pages

  Sioud, Mouldy ^a   Nyakas, Marta ^a   Sæbøe Larssen, Stein ^a   Mobergslien, Anne ^a   Aamdal, Steinar ^a   Kvalheim, Gunnar ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; INDOLEAMINE 2,3 DIOXYGENASE; IPILIMUMAB; SMALL INTERFERING RNA; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE;

ADOLESCENT; ARTICLE; AXILLARY LYMPH NODE; BENIGN TUMOR; BONE METASTASIS; BRAIN METASTASIS; CANCER IMMUNIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; DISEASE COURSE; DRUG WITHDRAWAL; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NEVUS; PALLIATIVE THERAPY; PRIMARY TUMOR; REVACCINATION; SKIN DEFECT; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

EID: 85020993157     PISSN: 16879627     EISSN: 16879635     Source Type: Journal    
DOI: 10.1155/2016/9639585     Document Type: Article

References (24)

1. J. Banchereau and R. M. Steinman, "Dendritic cells and the control of immunity," Nature, vol. 392, pp. 245-252, 1998.
2. K. Palucka and J. Banchereau, "Cancer immunotherapy via dendritic cells," Nature Reviews Cancer, vol. 12, no. 4, pp. 265-277, 2012.
3. A. Hoos, C. M. Britten, C. Huber, and J. O'Donnell-Tormey, "A methodological framework to enhance the clinical success of cancer immunotherapy," Nature Biotechnology, vol. 29, no. 10, pp. 867-870, 2011.
4. C. Guo, M. H. Manjili, J. R. Subjeck, D. Sarkar, P. B. Fisher, and X. Y. Wang, "Therapeutic cancer vaccines: past, present and future," Advances in Cancer Research, vol. 119, pp. 421-475, 2013.
5. R. M. Steinman, D. Hawiger, and M. C. Nussenzweig, "Tolerogenic dendritic cells," Annual Review of Immunology, vol. 21, no. 1, pp. 685-711, 2003.
6. D. H. Munn and A. L. Mellor, "Indoleamine 2, 3-dioxygenase and tumor-induced tolerance, "The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1147-1154, 2007.
7. P. Hubert, N. Jacobs, J.-H. Caberg, J. Boniver, and P. Delvenne, "The cross-talk between dendritic and regulatory T cells: good or evil?" Journal of Leukocyte Biology, vol. 82, no. 4, pp. 781-794, 2007.
8. A. L. Mellor and D. H. Munn, "Ido expression by dendritic cells: tolerance and tryptophan catabolism," Nature Reviews Immunology, vol. 4, no. 10, pp. 762-774, 2004.
9. L. M. Francisco, P. T. Sage, and A. H. Sharpe, "The PD-1 pathway in tolerance and autoimmunity," Immunological Reviews, vol. 236, no. 1, pp. 219-242, 2010.
10. K. L. Dennis, N. R. Blatner, F. Gounari, and K. Khazaie, "Current status of interleukin-10 and regulatory T-cells in cancer," Current Opinion in Oncology, vol. 25, no. 6, pp. 637-645, 2013.
11. P. Hwu, M. X. Du, R. Lapointe, M. Do, M. W. Taylor, and H. A. Young, "Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation," The Journal of Immunology, vol. 164, no. 7, pp. 3596-3599, 2000.
12. M. Wobser, H. Voigt, R. Houben, et al., "Dendritic cell based antitumor vaccination: impact of functional indoleamine 2, 3-dioxygenase expression," Cancer Immunology, Immunotherapy, vol. 56, no. 7, pp. 1017-1024, 2007.
13. P. Puccetti and U. Grohmann, "IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation," Nature Reviews Immunology, vol. 7, no. 10, pp. 817-823, 2007.
14. G. F. Flatekval and M. Sioud, "Modulation of dendritic cell maturation and function with mono-and bifunctional small interfering RNAs targeting indoleamine 2, 3-dioxygenase," Immunology, vol. 128, no. 1, pp. e837-e848, 2009.
15. T. Kondo, T. Kawai, and S. Akira, "Dissecting negative regulation of Toll-like receptor signaling," Trends in Immunology, vol. 33, no. 9, pp. 449-458, 2012.
16. M. Sioud, S. Saboe-Larssen, T. E. Hetland, J. Kaern, A. Mobergslien, and G. Kvalheim, "Silencing of indoleamine 2, 3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients," International Journal of Oncology, vol. 43, no. 1, pp. 280-288, 2013.
17. J. S. Weber, S. O'Day, W. Urba, et al., "Phase I/II study of ipilimumab for patients with metastatic melanoma," Journal of Clinical Oncology, vol. 26, no. 36, pp. 5950-5956, 2008.
18. L. Lee, M. Gupta, and S. Sahasranaman, "Immune Checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy," Journal of Clinical Pharmacology, vol. 56, no. 2, pp. 157-169, 2016.
19. J. Mackiewicz, "What is new in the treatment of advanced melanoma? State of the art," Contemporary Oncology, vol. 16, no. 5, pp. 363-370, 2012.
20. J. Weber, "Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response andimmune-related adverse events," The Oncologist, vol. 12, no. 7, pp. 864-872, 2007.
21. S. D. Brown, R. L. Warren, E. A. Gibb, et al., "Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival," Genome Research, vol. 24, no. 5, pp. 743-750, 2014.
22. C.-C. Chang, T. Ogino, D. W. Mullins, et al., "Defective human leukocyte antigen class I-associated antigen presentation caused by a novel β2-microglobulin loss-of-function in melanoma cells, "The Journal of Biological Chemistry, vol. 281, no. 27, pp. 18763-18773, 2006.
23. R. B. Holmgaard, D. Zamarin, D. H. Munn, J. D. Wolchok, and J. P. Allison, "Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4," Journal of Experimental Medicine, vol. 210, no. 7, pp. 1389-1402, 2013.
24. E. Vacchelli, F. Aranda, A. Eggermont, et al., "Trial watch: IDO inhibitors in cancer therapy," OncoImmunology, vol. 3, no. 10, Article ID e957994, 2014.